Stay updated on Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial
Sign up to get notified when there's something new on the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page.

Latest updates to the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAddition of Revision: v3.4.2 and removal of the government funding status notice appear to be site housekeeping; no changes to the study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a site-wide government funding status notice and updated the site revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.5%

- Check28 days agoChange DetectedShow glossary added; the QC criteria label text and capitalization changed (e.g., 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'), and a site revision indicator shows 'Revision: v3.4.0'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedFooter now displays Revision: v3.3.4, replacing the previous v3.3.3; this change does not affect the study details or any user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedA dedicated Locations section now lists Ontario as a study site. The page footer shows Revision: v3.3.3, and the old Ontario Locations entry and the HHS Vulnerability Disclosure note were removed.SummaryDifference0.2%

- Check85 days agoChange DetectedAdded a minor site revision note: 'Revision: v3.3.2' replacing the previous 'Revision: v3.3.1' on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page.